{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:44:33Z","timestamp":1764895473657,"version":"3.46.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Real-world data on the long-term use of fremanezumab for migraine prevention remain limited. This third interim analysis of the PEARL study addresses this gap by investigating the long-term effectiveness, safety, and tolerability of fremanezumab for up to 12 months of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PEARL is a 24-month, prospective, observational, Phase 4 study conducted in 11 European countries. Eligible participants were adults (\u2265\u200918 years) diagnosed with chronic or episodic migraine who received subcutaneous fremanezumab (225\u00a0mg monthly or 675\u00a0mg quarterly) and completed\u2009\u2265\u20096 months of treatment. The primary endpoint was defined as the proportion of participants achieving a\u2009\u2265\u200950% reduction in monthly migraine days (MMD) during the 6-month period following treatment initiation. Secondary endpoints included mean change from baseline to Month 12 in: average MMD, acute migraine medication use, and migraine-related disability scores, as measured by the Migraine Disability Assessment and the 6-item Headache Impact Test. Safety was assessed through the collection of adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At data cut-off (22 September 2022), 968 of 1140 enrolled participants were included in the effectiveness analysis with 58.5% achieving the primary endpoint. Sustained reductions in MMD, acute medication use, and disability scores were observed over 12 months, and no new safety signals were detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Findings from this third interim analysis of PEARL provide compelling evidence for the long-term effectiveness of fremanezumab in a large, real-world patient population. The results support the continued use of fremanezumab as a preventive strategy for migraine and underscore the value of integrating real-world evidence into migraine management.<\/jats:p>\n                    <jats:p>Trial registration number: EUPAS35111.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10072-025-08484-1","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T07:13:25Z","timestamp":1759302805000},"page":"6907-6921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term real-world effectiveness and safety of fremanezumab in 1140 patients with migraine and at least 6 months of treatment: third interim analysis of the\u00a0pan-European PEARL study"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0951-5804","authenticated-orcid":false,"given":"Messoud","family":"Ashina","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4691-3388","authenticated-orcid":false,"given":"Dimos D.","family":"Mitsikostas","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3803-3599","authenticated-orcid":false,"given":"Faisal Mohammad","family":"Amin","sequence":"additional","affiliation":[]},{"given":"Pinar","family":"Kokturk","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4668-6098","authenticated-orcid":false,"given":"Christoph J.","family":"Schankin","sequence":"additional","affiliation":[]},{"given":"Gurdal","family":"Sahin","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0796-4702","authenticated-orcid":false,"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4341-3801","authenticated-orcid":false,"given":"Paul J.","family":"Dorman","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0028-8836","authenticated-orcid":false,"given":"Tom\u00e1\u0161","family":"Ne\u017e\u00e1dal","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2872-4110","authenticated-orcid":false,"given":"Anne Christine","family":"Poole","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9611-7400","authenticated-orcid":false,"given":"Isabel Pav\u00e3o","family":"Martins","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6581-0483","authenticated-orcid":false,"given":"Marja-Liisa","family":"Sumelahti","sequence":"additional","affiliation":[]},{"given":"Verena","family":"Ramirez Campos","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-9300","authenticated-orcid":false,"given":"Andrew H.","family":"Ahn","sequence":"additional","affiliation":[]},{"given":"Hasan","family":"Akcicek","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-2113","authenticated-orcid":false,"given":"Cristina","family":"Tassorelli","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"8484_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/s0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, \u00d6zge A et al (2021) Migraine: epidemiology and systems of care. Lancet 397:1485\u20131495. https:\/\/doi.org\/10.1016\/s0140-6736(20)32160-7","journal-title":"Lancet"},{"key":"8484_CR2","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache Society (2021) The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache 61:1021\u20131039. https:\/\/doi.org\/10.1111\/head.14153","journal-title":"Headache"},{"key":"8484_CR3","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M (2020) Migraine. N Engl J Med 383:1866\u20131876. https:\/\/doi.org\/10.1056\/NEJMra1915327","journal-title":"N Engl J Med"},{"key":"8484_CR4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA et al (2013) Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS\u2010II). Headache 53:644\u2013655. https:\/\/doi.org\/10.1111\/head.12055","journal-title":"Headache"},{"key":"8484_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia 37:470\u2013485. https:\/\/doi.org\/10.1177\/0333102416678382","journal-title":"Cephalalgia"},{"key":"8484_CR6","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/head.13661","volume":"59","author":"CEJ Ceriani","year":"2019","unstructured":"Ceriani CEJ, Wilhour DA, Silberstein SD (2019) Novel medications for the treatment of migraine. Headache 59:1597\u20131608. https:\/\/doi.org\/10.1111\/head.13661","journal-title":"Headache"},{"key":"8484_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0875-x","volume":"19","author":"N Vandenbussche","year":"2018","unstructured":"Vandenbussche N, Laterza D, Lisicki M, Lloyd J, Lupi C, Tischler H et al (2018) Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain 19:50. https:\/\/doi.org\/10.1186\/s10194-018-0875-x","journal-title":"J Headache Pain"},{"key":"8484_CR8","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s13311-022-01230-x","volume":"19","author":"F Cohen","year":"2022","unstructured":"Cohen F, Yuan H, DePoy EMG, Silberstein SD (2022) The arrival of anti-CGRP monoclonal antibodies in migraine. Neurotherapeutics 19:922\u2013930. https:\/\/doi.org\/10.1007\/s13311-022-01230-x","journal-title":"Neurotherapeutics"},{"key":"8484_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061656","volume":"11","author":"D Moreno-Ajona","year":"2022","unstructured":"Moreno-Ajona D, Villar-Martinez MD, Goadsby PJ (2022) New generation gepants: migraine acute and preventive medications. J Clin Med 11:1656. https:\/\/doi.org\/10.3390\/jcm11061656","journal-title":"J Clin Med"},{"issue":"Suppl 3","key":"8484_CR10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/head.13379","volume":"58","author":"SJ Tepper","year":"2018","unstructured":"Tepper SJ (2018) History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from translational research to treatment. Headache 58(Suppl 3):238\u2013275. https:\/\/doi.org\/10.1111\/head.13379","journal-title":"Headache"},{"key":"8484_CR11","unstructured":"Teva Pharmaceuticals (2022) AJOVY\u00ae (fremanezumab-vfrm) [package insert]. Teva Pharmaceuticals, North Wales, PA. https:\/\/www.ajovy.com\/globalassets\/ajovy\/ajovy-pi.pdf. Accessed September 2024"},{"key":"8484_CR12","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1474-4422(15)00249-5","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R et al (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14:1081\u20131090. https:\/\/doi.org\/10.1016\/S1474-4422(15)00249-5","journal-title":"Lancet Neurol"},{"key":"8484_CR13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(15)00245-8","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC et al (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14:1091\u20131100. https:\/\/doi.org\/10.1016\/S1474-4422(15)00245-8","journal-title":"Lancet Neurol"},{"issue":"19","key":"8484_CR14","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine. JAMA 319:1999\u20132008. https:\/\/doi.org\/10.1001\/jama.2018.4853","journal-title":"JAMA"},{"key":"8484_CR15","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377:2113\u20132122. https:\/\/doi.org\/10.1056\/NEJMoa1709038","journal-title":"N Engl J Med"},{"key":"8484_CR16","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394:1030\u20131040. https:\/\/doi.org\/10.1016\/S0140-6736(19)31946-4","journal-title":"Lancet"},{"key":"8484_CR17","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/head.14097","volume":"61","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, Cohen JM, Galic M, Seminerio MJ, Yeung PP, Aycardi E et al (2021) Effects of fremanezumab in patients with chronic migraine and comorbid depression: subgroup analysis of the randomized HALO CM study. Headache 61:662\u2013672. https:\/\/doi.org\/10.1111\/head.14097","journal-title":"Headache"},{"issue":"1","key":"8484_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01173-8","volume":"21","author":"SD Silberstein","year":"2020","unstructured":"Silberstein SD, Cohen JM, Seminerio MJ, Yang R, Ashina S, Katsarava Z (2020) The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain 21:114. https:\/\/doi.org\/10.1186\/s10194-020-01173-8","journal-title":"J Headache Pain"},{"key":"8484_CR19","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/jamia\/ocab164","volume":"28","author":"C Yuan","year":"2021","unstructured":"Yuan C, Ryan PB, Ta CN, Kim JH, Li Z, Weng C (2021) From clinical trials to clinical practice: how long are drugs tested and then used by patients? J Am Med Inform Assoc 28:2456\u20132460. https:\/\/doi.org\/10.1093\/jamia\/ocab164","journal-title":"J Am Med Inform Assoc"},{"key":"8484_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01561-w","volume":"24","author":"P Barbanti","year":"2023","unstructured":"Barbanti P, Egeo G, Aurilia C, Torelli P, Finocchi C, d\u2019Onofrio F et al (2023) Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study. J Headache Pain 24:30. https:\/\/doi.org\/10.1186\/s10194-023-01561-w","journal-title":"J Headache Pain"},{"key":"8484_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/03331024241280496","volume":"44","author":"F Ahmed","year":"2024","unstructured":"Ahmed F, Khan R, Dorsey S, Delrosario H, Khalil M (2024) Three year outcome of fremanezumab in refractory chronic migraine patients: real-world data from the hull migraine clinic, UK (Abstract P.09). Cephalalgia 44:57. https:\/\/doi.org\/10.1177\/03331024241280496","journal-title":"Cephalalgia"},{"key":"8484_CR22","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1111\/head.13956","volume":"60","author":"A Alex","year":"2020","unstructured":"Alex A, Vaughn C, Rayhill M (2020) Safety and tolerability of 3 CGRP monoclonal antibodies in practice: a retrospective cohort study. Headache 60:2454\u20132462. https:\/\/doi.org\/10.1111\/head.13956","journal-title":"Headache"},{"key":"8484_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01593-2","volume":"24","author":"A Straube","year":"2023","unstructured":"Straube A, Broessner G, Gaul C, Hamann X, Hipp J, Kraya T et al (2023) Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the finesse study. J Headache Pain 24:59. https:\/\/doi.org\/10.1186\/s10194-023-01593-2","journal-title":"J Headache Pain"},{"key":"8484_CR24","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2217\/pmt-2021-0015","volume":"11","author":"M Ashina","year":"2021","unstructured":"Ashina M, Amin FM, Kokturk P, Cohen JM, Konings M, Tassorelli C et al (2021) Pearl study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine. Pain Manag 11:647\u2013654. https:\/\/doi.org\/10.2217\/pmt-2021-0015","journal-title":"Pain Manag"},{"key":"8484_CR25","doi-asserted-by":"publisher","first-page":"333102423121498","DOI":"10.1177\/03331024231214987","volume":"43","author":"M Ashina","year":"2023","unstructured":"Ashina M, Mitsikostas DD, Amin FM, Kokturk P, Schankin CJ, Sahin G et al (2023) Real-world effectiveness of fremanezumab for the preventive treatment of migraine: interim analysis of the pan-European, prospective, observational, phase 4 PEARL study. Cephalalgia 43:3331024231214987. https:\/\/doi.org\/10.1177\/03331024231214987","journal-title":"Cephalalgia"},{"issue":"Suppl 1","key":"8484_CR26","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/ene.15461","volume":"29","author":"M Ashina","year":"2022","unstructured":"Ashina M, Mitsikostas D, Amin F, Kokturk P, Poole A, Sahin G et al (2022) Effectiveness of fremanezumab for preventive treatment of migraine: the observational PEARL study (Abstract EPR-035). Eur J Neurol 29(Suppl 1):192. https:\/\/doi.org\/10.1111\/ene.15461","journal-title":"Eur J Neurol"},{"key":"8484_CR27","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society IHS (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"issue":"6 Suppl 1","key":"8484_CR28","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1212\/wnl.56.suppl_1.s20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J (2001) Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. Neurology 56(6 Suppl 1):S20\u2013S28. https:\/\/doi.org\/10.1212\/wnl.56.suppl_1.s20","journal-title":"Neurology"},{"key":"8484_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3988\/jcn.2008.4.4.158","volume":"4","author":"HE Shin","year":"2008","unstructured":"Shin HE, Park JW, Kim YI, Lee KS (2008) Headache impact test-6 (HIT-6) scores for migraine patients: their relation to disability as measured from a headache diary. J Clin Neurol 4:158\u2013163. https:\/\/doi.org\/10.3988\/jcn.2008.4.4.158","journal-title":"J Clin Neurol"},{"key":"8484_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12093218","volume":"12","author":"AA Argyriou","year":"2023","unstructured":"Argyriou AA, Dermitzakis EV, Xiromerisiou G, Rallis D, Soldatos P, Litsardopoulos P et al (2023) Predictors of response to Fremanezumab in migraine patients with at least three previous preventive failures: post hoc analysis of a prospective, multicenter, real-world Greek registry. J Clin Med 12:3218. https:\/\/doi.org\/10.3390\/jcm12093218","journal-title":"J Clin Med"},{"key":"8484_CR31","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40120-024-00591-z","volume":"13","author":"P Barbanti","year":"2024","unstructured":"Barbanti P, Egeo G, Proietti S, d\u2019Onofrio F, Aurilia C, Finocchi C et al (2024) Assessing the long-term (48-week) effectiveness, safety, and tolerability of fremanezumab in migraine in real life: insights from the multicenter, prospective, FRIEND3 study. Neurol Ther 13:611\u2013624. https:\/\/doi.org\/10.1007\/s40120-024-00591-z","journal-title":"Neurol Ther"},{"key":"8484_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01433-9","volume":"23","author":"CK Cullum","year":"2022","unstructured":"Cullum CK, Do TP, Ashina M, Bendtsen L, Hugger SS, Iljazi A et al (2022) Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study. J Headache Pain 23:61. https:\/\/doi.org\/10.1186\/s10194-022-01433-9","journal-title":"J Headache Pain"},{"key":"8484_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01507-8","volume":"23","author":"AP Andreou","year":"2022","unstructured":"Andreou AP, Fuccaro M, Hill B, Murphy M, Caponnetto V, Kilner R et al (2022) Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis. J Headache Pain 23:139. https:\/\/doi.org\/10.1186\/s10194-022-01507-8","journal-title":"J Headache Pain"},{"key":"8484_CR34","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(24)00025-5","volume":"23","author":"C Tassorelli","year":"2024","unstructured":"Tassorelli C, Nagy K, Pozo-Rosich P, Lanteri-Minet M, Sacco S, Ne\u017e\u00e1dal T et al (2024) Safety and efficacy of Atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. Lancet Neurol 23:382\u2013392. https:\/\/doi.org\/10.1016\/S1474-4422(24)00025-5","journal-title":"Lancet Neurol"},{"issue":"Suppl 1","key":"8484_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s10194-024-01793-4","volume":"25","author":"S Uzun","year":"2024","unstructured":"Uzun S, Frejvall U, \u00d6zkaya Sahin G, Sahin G (2024) Real-world evidence for frequency of constipation with the use of anti-CGRP monoclonal antibodies in chronic migraine (Abstract P015). J Headache Pain 25(Suppl 1):17. https:\/\/doi.org\/10.1186\/s10194-024-01793-4","journal-title":"J Headache Pain"},{"key":"8484_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21:61. https:\/\/doi.org\/10.1186\/s10194-020-01127-0","journal-title":"J Headache Pain"},{"key":"8484_CR37","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L et al (2021) Atogepant for the preventive treatment of migraine. N Engl J Med 385:695\u2013706. https:\/\/doi.org\/10.1056\/NEJMoa2035908","journal-title":"N Engl J Med"},{"key":"8484_CR38","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0140-6736(23)01049-8","volume":"402","author":"P Pozo-Rosich","year":"2023","unstructured":"Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U et al (2023) Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 402:775\u2013785. https:\/\/doi.org\/10.1016\/S0140-6736(23)01049-8","journal-title":"Lancet"},{"key":"8484_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2377347","author":"H Wen","year":"2024","unstructured":"Wen H, Ding Y, Chen F (2024) A real-world pharmacovigilance study of FDA adverse event reporting system events for Atogepant. Expert Opin Drug Saf 1\u20138. https:\/\/doi.org\/10.1080\/14740338.2024.2377347","journal-title":"Expert Opin Drug Saf"},{"key":"8484_CR40","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/bph.15585","volume":"179","author":"ML Garelja","year":"2022","unstructured":"Garelja ML, Walker CS, Hay DL (2022) CGRP receptor antagonists for migraine. Are they also AMY(1) receptor antagonists? Br J Pharmacol 179:454\u2013459. https:\/\/doi.org\/10.1111\/bph.15585","journal-title":"Br J Pharmacol"},{"key":"8484_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s10194-022-01425-9","volume":"23","author":"S Hage La Cour","year":"2022","unstructured":"Hage La Cour S, Juhler K, Kogelman LJA, Olesen J, Klaerke DA, Kristensen DM et al (2022) Characterization of erenumab and Rimegepant on calcitonin gene-related peptide induced responses in xenopus laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 receptor. J Headache Pain 23:59. https:\/\/doi.org\/10.1186\/s10194-022-01425-9","journal-title":"J Headache Pain"},{"key":"8484_CR42","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1212\/WNL.0000000000201332","volume":"99","author":"J Ailani","year":"2022","unstructured":"Ailani J, Kaiser EA, Mathew PG, McAllister P, Russo AF, Velez C et al (2022) Role of calcitonin gene-related peptide on the gastrointestinal symptoms of migraine-clinical considerations: a narrative review. Neurology 99:841\u2013853. https:\/\/doi.org\/10.1212\/WNL.0000000000201332","journal-title":"Neurology"},{"key":"8484_CR43","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1046\/j.1526-4610.2003.03206.x","volume":"43","author":"JE Magnusson","year":"2003","unstructured":"Magnusson JE, Becker WJ (2003) Migraine frequency and intensity: relationship with disability and psychological factors. Headache 43:1049\u20131059. https:\/\/doi.org\/10.1046\/j.1526-4610.2003.03206.x","journal-title":"Headache"},{"key":"8484_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0998-8","volume":"20","author":"R Cowan","year":"2019","unstructured":"Cowan R, Cohen JM, Rosenman E, Iyer R (2019) Physician and patient preferences for dosing options in migraine prevention. J Headache Pain 20:50. https:\/\/doi.org\/10.1186\/s10194-019-0998-8","journal-title":"J Headache Pain"},{"key":"8484_CR45","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/head.14068","volume":"61","author":"DM Hines","year":"2021","unstructured":"Hines DM, Shah S, Multani JK, Wade RL, Buse DC, Bensink M (2021) Erenumab patient characteristics, medication adherence, and treatment patterns in the United States. Headache 61:590\u2013602. https:\/\/doi.org\/10.1111\/head.14068","journal-title":"Headache"},{"key":"8484_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01415-x","volume":"23","author":"MT Driessen","year":"2022","unstructured":"Driessen MT, Cohen JM, Thompson SF, Patterson-Lomba O, Seminerio MJ, Carr K et al (2022) Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine. J Headache Pain 23:56. https:\/\/doi.org\/10.1186\/s10194-022-01415-x","journal-title":"J Headache Pain"},{"key":"8484_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01413-z","volume":"23","author":"LJ Krasenbaum","year":"2022","unstructured":"Krasenbaum LJ, Pedarla VL, Thompson SF, Tangirala K, Cohen JM, Driessen MT (2022) A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States. J Headache Pain 23:54. https:\/\/doi.org\/10.1186\/s10194-022-01413-z","journal-title":"J Headache Pain"},{"key":"8484_CR48","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS (2018) Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther 35:1763\u20131774. https:\/\/doi.org\/10.1007\/s12325-018-0805-y","journal-title":"Adv Ther"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08484-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08484-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08484-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:40:27Z","timestamp":1764895227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08484-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["8484"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08484-1","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"11 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The PEARL study protocol was approved by the Independent Ethics Committee\/Institutional Review Board in the 11 participating European countries, as required by local law, and all relevant local data protection laws were followed. As PEARL is a non-interventional, prospective study, no study procedures were performed beyond the participants\u2019 care in real-world clinical practice. Informed consent was obtained from all participants as part of the study inclusion criteria; participants agreed for their clinical data to be recorded anonymously and had the right to withdraw their consent at any time during the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}},{"value":"Messoud Ashina has received personal fees and declares PI\/collaborator in clinical trials for AbbVie, Amgen, AstraZeneca, Eli Lilly, GlaxoSmithKline, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals; and institutional research grants from the Lundbeck Foundation, the Novo Nordisk Foundation, Lundbeck, and Novartis. Dimos D. Mitsikostas has received fees and travel grants from Allergan, Amgen, Bayer, Biogen, Cefaly, electroCore, Eli Lilly, Genesis Pharma, Merck Serono, Merz, Mylan, Novartis, Roche, Sanofi Genzyme, Specifar, and Teva Pharmaceuticals. Faisal Mohammad Amin has received personal fees for lecturing and\/or participation in advisory boards from AbbVie, Eli Lilly, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals; and research grants from the Lundbeck Foundation. Pinar Kokturk, Verena Ramirez Campos, and Hasan Akcicek are employees and\/or shareholders of Teva Pharmaceuticals. Christoph J. Schankin declares consulting, advisory boards, presentations, and travel support from AbbVie, Allergan, Almirall, Amgen, Eli Lilly, Gr\u00fcnenthal, Lundbeck, MindMed, Novartis, Pfizer, and Teva Pharmaceuticals; part-time employment with Zynnon; and research support from the Baasch-Medicus Foundation, the Eye on Vision Foundation, the German Migraine and Headache Society, the Swiss Heart Foundation, Teva Pharmaceuticals, Visual Snow Initiative, and Visual Snow Syndrome Germany e.V. Gurdal Sahin declares advisory boards and\/or PI in clinical trials for AbbVie, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals; and research support from Vinnova (Sweden\u2019s innovation agency), Lund University, and the Swedish Neurological Association. Patricia Pozo-Rosich declares grant\/research support from AbbVie, AGAUR, EraNet NEURON, Instituto Investigaci\u00f3\u00f3n Carlos III, MINECO, Novartis, RIS3CAT FEDER, and Teva Pharmaceuticals; and consultancy or education for AbbVie, Amgen, Dr. Reddy\u2019s, Eli Lilly, Lundbeck, Novartis, Organon, Pfizer, and Teva Pharmaceuticals. Paul J. Dorman declares lecture fees, advisory boards, educational support, and research with AbbVie, electroCore, Eli Lilly, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals. Tom\u00e1\u0161 Ne\u017e\u00e1dal declares consulting, speaking fees, and travel grants from Eli Lilly, Glenmark, Lundbeck, Novartis, Organon, Pfizer, St. Jude Medical, Teva Pharmaceuticals, and UCB; and advisory boards and PI in clinical trials for AbbVie, Amgen, Eli Lilly, Lundbeck, Neurocrine, Novartis, Teva Pharmaceuticals, and UCB. Anne Christine Poole declares advisory boards, clinical studies, and\/or lecturing for AbbVie, Eli Lilly, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals. Isabel Pav\u00e3o Martins declares consultancy or education and\/or PI in clinical trials for AbbVie, Allergan, Eli Lilly, Lundbeck, Novartis, Organon, Pfizer, Teva Pharmaceuticals, and Zambon. Marja-Liisa Sumelahti declares lectures, advisory boards, educational support, and research with AbbVie, Eli Lilly, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals. Andrew H. Ahn is a former employee of Teva Pharmaceuticals. Cristina Tassorelli declares consulting or speaking fees and\/or travel grants, advisory boards, symposia, and\/or PI\/collaboration in clinical trials for AbbVie, Chordate, Domp\u00e9, Eli Lilly, Ipsen, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals; PI in clinical trials for AbbVie, Chordate, Eli Lilly, Ipsen, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals; and research grants from AbbVie, the European Commission, the Italian Ministry of Health, the Migraine Research Foundation, and the Italian Multiple Sclerosis Foundation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}